Antiandrogenic therapy can cause coronary arterial disease

Kuan Chou Chen, Chiung Chi Peng, Hsiu Mei Hsieh, Chiung Huei Peng, Chiu-Lan Hsieh, Chien Ning Huang, Charng Cherng Chyau, Hui Er Wang, Robert Y. Peng

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aim: To study the change of lipid metabolism by antiandrogen therapy in patients with prostate cancer. Materials and methods: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II profiles in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN 0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy. Results: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of triglyceride levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease. Conclusions: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II profiles, other than the well-known hyperglyceridemic effect caused by estrogen.

Original languageEnglish
Pages (from-to)886-891
Number of pages6
JournalInternational Journal of Urology
Volume12
Issue number10
DOIs
Publication statusPublished - 2005 Oct 1

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Chen, K. C., Peng, C. C., Hsieh, H. M., Peng, C. H., Hsieh, C-L., Huang, C. N., ... Peng, R. Y. (2005). Antiandrogenic therapy can cause coronary arterial disease. International Journal of Urology, 12(10), 886-891. https://doi.org/10.1111/j.1442-2042.2005.01145.x